ME Therapeutics Holdings, Inc. ( (TSE:METX) ) has provided an update.
ME Therapeutics Holdings Inc. has engaged Lucosky Brookman LLP to explore a potential uplisting to a senior national securities exchange such as the NASDAQ or NYSE. This strategic move is aimed at enhancing the company’s visibility, strengthening investor confidence, and supporting long-term growth as it advances towards clinical trials for its lead G-CSF antibody candidate and mRNA drug discovery program. While ME Therapeutics plans to meet the necessary financial and regulatory requirements for uplisting, there is no guarantee of acceptance or timing for completion.
More about ME Therapeutics Holdings, Inc.
ME Therapeutics Holdings Inc. is a Vancouver-based preclinical stage biotechnology company focused on the discovery and development of novel immuno-oncology therapeutics. The company’s primary aim is to target immune suppression in cancer by overcoming the suppressive effects of myeloid cells to enhance anti-cancer immunity.
YTD Price Performance: 87.50%
Average Trading Volume: 418
Technical Sentiment Consensus Rating: Sell
See more data about METX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com